Luminex Corporation was incorporated in May 1995 and began commercial production of the first generation system in 1997. Luminex® (NASDAQ: LMNX) develops, manufactures and markets innovative biological testing technologies with applications throughout the life science and diagnostic industries. The Company’s open-architecture xMAP® Technology enables large numbers of biological tests (bioassays) to be conducted and analyzed quickly, cost-effectively and accurately. Systems using xMAP Technology perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer. Using lasers and high-speed digital-signal processors, the analyzer simultaneously identifies the bioassay and measures the results, all in real time.
Luminex Vision Statement: Breakthrough solutions to improve health and advance science.

Austin, US
797 (est)
Luminex is headquartered in Austin, US

Luminex Locations

Austin, US
Shanghai, CN
Madison, US
's-Hertogenbosch, NL
Toronto, CA
Minato-ku, JP

Luminex Metrics

Luminex Summary

Market capitalization

$880 M

Closing share price

Luminex's current market capitalization is $880 M.

Luminex Financials

Luminex's revenue is $238 M in FY, 2015 which is 4.73% increase from the previous period.
FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015


$10.7 M$227 M$238 M

Gross profit

$144 M$160 M$169 M

Operating income

$4.77 M$28.1 M$37.4 M

Operating expense total

$139 M$132 M$131 M

Income tax expense

$6.12 M$9.46 M$10.4 M

Net Income

$7.1 M$39 M$36.9 M

Operating cash flow

$25.1 M$23.8 M$36.9 M

    Luminex Market Value History

    Luminex Online Presence

    Luminex Company Life

    You may also be interested in